Dosage protocol · Immune & Inflammation
Thymosin Alpha-1 10 mg
Typical daily range: 300–500 mcg once daily (gradual titration).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 300–500 mcg once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.
Reconstitution
Thymosin Alpha-1 dosage chart
| Week | Dose | Draw |
|---|---|---|
| Week 1 | 300 mcg0.3 mg | 9 units0.09 mL |
| Weeks 2–8 | 500 mcg0.5 mg | 15 units0.15 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Thymosin alpha-1, also known by the drug name thymalfasin, is a synthetic 28-amino-acid peptide originally identified from thymic tissue extracts.[1] It is classified as an immune-modulating peptide rather than a direct antimicrobial or antiviral agent — it does not kill pathogens itself but is studied for its influence on how immune cells communicate and respond.
Thymosin alpha-1 is easily confused with other thymosin-family peptides, most notably thymosin beta-4 (the peptide behind research compounds like TB-500), which has an entirely different research focus in tissue repair and wound healing. This article covers thymosin alpha-1 only.[7]
Benefits & side effects
Chronic hepatitis B is the most studied use, but a Cochrane systematic review concluded available trials did not provide strong enough evidence for definitive conclusions about efficacy and safety, calling for better-designed studies.[3] Older research also paired it with interferon alpha for chronic hepatitis C, though modern direct-acting antivirals are now the standard of care, limiting that data's relevance today.
More recent research covers sepsis and severe COVID-19. A meta-analysis of immunomodulatory therapy for sepsis found potential benefit signals but flagged significant limitations in trial quality, and one COVID-19 study reported an association between thymosin alpha-1 use and reduced mortality in severe cases — a signal the authors said needed further trials to confirm.[4] None of this supports the broader online framing of thymosin alpha-1 as a general immunity or longevity peptide.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
Reconstitution
Your dose
Other vial sizes